SCHEMBL677380

SCHEMBL677380

COP(=O)(OC)[C@@H]([C]=O)Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LAP3 P28838 5/20 0.49
ANPEP P15144 2/20 0.40
ACP3 P15309 1/20 0.39
TAAR1 Q96RJ0 4/20 0.37
SLC6A2 P23975 2/20 0.37
SIGMAR1 Q99720 2/20 0.37
MAOA P21397 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
CYP2A6 P11509 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
CYP1A2 P05177 1/20 0.36
TRPA1 O75762 1/20 0.36
EPHX1 P07099 1/20 0.35
SLC18A2 Q05940 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL678819 1.00 LAP3 (0.49) LAP3ANPEPACP3TAAR1SLC6A2
SCHEMBL3696122 1.00 LAP3 (0.49) LAP3ANPEPACP3TAAR1SLC6A2
SCHEMBL13431344 0.78 LAP3 (0.54) LAP3ANPEPACP3TAAR1SLC6A2
SCHEMBL10714483 0.75 LAP3 (0.56) LAP3ANPEPACP3PPARGPPARA
SCHEMBL11167921 0.75 LAP3 (0.70) LAP3ANPEPTAAR1SLC6A2SIGMAR1
SCHEMBL9665263 0.74 LAP3 (0.48) LAP3ANPEPACP3
SCHEMBL7387949 0.72 LAP3 (0.53) LAP3ANPEPACP3PPARGPPARA
SCHEMBL9668104 0.72 LAP3 (0.53) LAP3ANPEPACP3PPARGPPARA
SCHEMBL677381 0.72 LAP3 (0.49) LAP3ANPEPACP3TAAR1SLC6A2
SCHEMBL3143113 0.72 LAP3 (0.53) LAP3ANPEPACP3PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed
US-20110046090-A1 MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS BRAINCELLS INC. (US) 2011-02-24 US disclosed
WO-2010111136-A2 ALISKIREN MODULATION OF NEUROGENESIS BRAINCELLS, INC. (US) 2010-09-30 WO disclosed
US-20090197823-A1 ALISKIREN MODULATION OF NEUROGENESIS BRAINCELLS, INC. (US) 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197823-A1 ALISKIREN MODULATION OF NEUROGENESIS DCX, NGF, BDNF LAP3 2161/4885ANPEP 501/4885ACP3 747/4885
US-20110046090-A1 MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS GAP43, GABRB1, GABRB3 LAP3 4494/4885ANPEP 2698/4885ACP3 1064/4885
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF LAP3 738/4885ANPEP 77/4885ACP3 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.